Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Car4-positive adipocyte progenitor cells adapt to the aging environment and work as protection against ROS via glutathione metabolism.

Scientific reports·2025
Same author

Evaluation of the efficacy of aromatherapy and complementary yoga on indicators of medication regimen complexity: A retrospective study.

BMC complementary medicine and therapies·2025
Same author

Sex difference in BAT thermogenesis depends on PGC-1α-mediated phospholipid synthesis in mice.

Nature communications·2025
Same author

Unexpected Remission of Bilateral Hyperaldosteronism After Unilateral Cortisol-Producing Adenoma Resection: A Report of Two Cases.

Case reports in endocrinology·2025
Same author

Clinical neuropathology of early-stage Pick's disease initially diagnosed as depressive disorder: A case report and case series comparison.

PCN reports : psychiatry and clinical neurosciences·2025
Same author

Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report.

Hepatology research : the official journal of the Japan Society of Hepatology·2025
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

[Current therapy for hepatocellular carcinoma].

Kenji Ikeda1

  • 1Department of Hepatology, Toranomon Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 12, 2010
PubMed
Summary
This summary is machine-generated.

Treatment for hepatocellular carcinoma (HCC) varies by stage and liver function. Early-stage HCC is best treated with surgery, while intermediate stages benefit from transcatheter arterial chemoembolization. Advanced HCC treatments are still under investigation.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatobiliary Medicine
  • Surgical Oncology
  • Interventional Radiology

Background:

  • Hepatocellular carcinoma (HCC) treatment strategies are tailored to disease stage and patient liver function.
  • Multimodality treatment approaches are standard for managing HCC.
  • Optimal therapeutic strategies continue to evolve for different stages of HCC.

Purpose of the Study:

  • To review current multimodality treatment options for hepatocellular carcinoma (HCC).
  • To outline the efficacy of various treatments based on HCC stage and liver function.
  • To discuss the role of emerging therapies in advanced HCC management.

Main Methods:

  • Review of established treatment modalities for HCC.
  • Analysis of treatment effectiveness based on tumor stage, size, and number.
  • Evaluation of percutaneous local ablation and transcatheter arterial chemoembolization (TACE).
  • Consideration of systemic chemotherapy and targeted therapy for advanced HCC.

Main Results:

  • Surgical resection is the primary curative option for early-stage HCC.
  • Radiofrequency ablation demonstrates high efficacy in local recurrence and survival rates for early-stage HCC.
  • Transcatheter arterial chemoembolization (TACE) is effective in prolonging survival for intermediate-stage HCC.
  • Evidence for chemotherapy efficacy in advanced HCC remains limited.
  • The utility of sorafenib in Japanese advanced HCC patients requires further investigation.

Conclusions:

  • Treatment selection for HCC is stage-dependent, ranging from resection for early disease to TACE for intermediate stages.
  • Percutaneous ablation and TACE are key interventions for specific HCC stages.
  • Further research is needed to establish effective treatments for advanced HCC, including the role of targeted therapies like sorafenib in diverse populations.